

GenesisCare Foundation Compassionate Access Programme

Who is eligible for the Programme?

Patients with medically inoperable, borderline resectable, locally advanced or locally recurrent pancreatic cancer, without any evidence of metastatic disease, constitute the group potentially eligible for the programme.

■ Inclusion criteria

- Histologically/cytologically proven pancreatic malignancy. Where not available, NHS MDT consensus confirmation of likely malignancy is required.
- Locally advanced, unresectable, or borderline resectable disease (abutment of superior mesenteric artery, coeliac axis, superior mesenteric vein, or portal vein); or locally recurrent disease after previous pancreatectomy; or medically inoperable disease
- ECOG performance status 0–2
- No contraindication to MRI
- Life expectancy >6 months
- Recovered from the effects of previous treatment with a minimum of two weeks break between previous treatment and first SABR fraction

- Axial imaging of the thorax, abdomen, and pelvis within six weeks of referral date, excluding metastatic disease; FDG PET is not mandated but is strongly preferred
- Adequate organ function as follows: haemoglobin > 90 g/L, absolute neutrophil count > $1.5 \times 10^9/L$, platelets > $80 \times 10^9/L$, bilirubin < 3.0 times upper limit of normal range, INR < 1.3 or correctable with vitamin K, AST or ALT < 5.0 times normal range, Creatinine < 200 $\mu\text{mol/L}$

Patients with operable disease are excluded, as they generally have the option of bridging chemotherapy within the NHS if surgery is not immediately available. It is preferred, but not mandated, that all patients referred have had at least three months of chemotherapy prior to SABR.

■ Exclusion criteria

- Frank invasion of adjacent gastrointestinal structures, as evidenced clinically and/or radiologically
- Patients with active hepatitis or clinically significant liver failure (encephalopathy, oesophageal varices, portal hypertension), or patients with chronic active gastro- duodenal ulcer disease
- Prior overlapping abdominal radiotherapy. Prior breast, pelvic and lung radiation is permitted, as long as no overlap occurs
- Therapeutic anticoagulation is a relative contra-indication